Industry Outlook 2025: Business Viability and Global Collaboration

Being realistic about the viability of business, finances, technology, and the success of drug products, as well as getting back to the basics, are trends from 2024 that have impacted the bio/pharmaceutical industry, according to Alexander Seyf, CEO and Co-Founder of Autolomous. “We're seeing people going back to the drawing board and thinking at the same time [not just the] science, but also the viability of having it as a business,” says Seyf. “I think that's a very positive [trend], because sometimes we need little bit of nudge in the in the shoulder to really guide us forward.”

Seyf also stresses that the industry needs to break out of a “siloed” mentality and embrace working together. Part of making business viable is harmonization and thinking globally. “And one of the key elements, I would say, is we need support from governments. We need support from policy makers,” Seyf says. “And right now, I've seen a good trend in the United States this year that they begin to realize that this is an industry to invest in, and we need to think a little bit differently than we do for pharma. However, I also see the whole kind of healthcare situation in US can be little bit difficult to move it to a more rational change, or to more radical change. However, in Europe, we have the benefit of national health services, and … politicians start realizing the new modality of medicine. There have been a number of talks, and, also, I believe it was mentioned in the parliament. So, we see good trends, both from a Europe perspective, but also a UK [United Kingdom] perspective.”

Click the video above to watch the full interview.

About the speaker

Alexander Seyf, CEO and Co-Founder of Autolomous

Alexander Seyf is CEO and Co-Founder of Autolomous.